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A B S T R A C T
Heart failure remains a leading cause of cardiovascular morbidity and mortality following myocardial
infarction. Progressive cardiac remodeling results in altered shape and geometry of left ventricle with
increased LV end diastolic volume and LV dilatation, reduced ejection fraction and heart failure. Medical
therapy is the mainstay of management. Surgical ventricular restoration to reverse cardiac remodelling
has been attempted with varying results. Percutaneous ventricular restoration using ventricular partition
device is emerging as a new strategy for the treatment of ischemic heart failure.
Research studies and recent meta-analysis have shown a success rate of 90% in device deployment.
Procedural complications occurred in 6.6% patients. Device implantation resulted in improvement of
Quality of Life, NYHA class and six minutes walking distance. Left ventricular end diastolic volume and
left ventricular end systolic volume decreased by about 20% on 1–3 year follow up. Mortality and
recurrent hospitalization for heart failure showed reduction after device implantation.
ã 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Occlusion of left anterior descending coronary artery results in
acute myocardial infarction involving the anterior wall and antero-
apical portion of left ventricle (LV). This often results in progressive
LV remodeling resulting in LV dilatation, aneurysm formation and
chronic heart failure.1 LV remodeling is characterized by alteration
in cardiac structure, geometry and shape in response to
pathological stress of myocardial infarction, scarring and* Correspondence to: Flat No 403, Golden Sobhagya, B-81, Rajendra Marg, Bapu
Nagar, Jaipur 15, India.
E-mail address: gupta98tanya@gmail.com (S. Gupta).
http://dx.doi.org/10.1016/j.ihj.2016.11.324
0019-4832/ã 2016 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/).
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doi.org/10.1016/j.ihj.2016.11.324interstitial ﬁbrosis.2 There is an increase in left ventricular end-
diastolic volume (LVEDV) with LV dilatation, reduced ejection
fraction (EF) and eventually heart failure (HF). Since cardiac
remodeling is a progressive phenomenon, there is a need to reverse
the process of LV remodeling to improve survival and to reduce
mortality.3 After the development of heart failure, quality of life
(QOL) becomes poor due to frequent hospitalizations and impaired
physical strength. The mortality remains unacceptably high after
the development of heart failure.4 Optimal medical treatment of
dilated ischemic heart failure includes intensive risk reduction
with life style modiﬁcations, angiotensin converting enzyme (ACE)
inhibitors/angiotensin receptor blockers (ARB), beta blockers,
aldosterone antagonists, diuretics, antiplatelet drugs and India. This is an open access article under the CC BY-NC-ND license (http://
 restoration in chronic heart failure, Indian Heart J (2016), http://dx.
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coronary intervention (PCI) or coronary artery bypass surgery
(CABG). In patients refractory to optimal medical therapy (OMT),
cardiac resynchronization therapy (CRT) or automatic implantable
deﬁbrillator (AICD) may be indicated. Ventricular assist device
(VAD) and cardiac transplantation are considered as the last
options in refractory heart failure.7
Progressive remodeling occurred in 33% patients of myocardial
infarction enrolled in GISSI-3 TRIAL (n = 13679).8 Therapies which
reverse remodeling, are becoming the cornerstone in the
management of dilated ischemic heart failure. Surgical ventricular
restoration (SVR) has been performed with the aim to reduce the
LV volume and to restore the elliptical shape. SVR is usually done
with CABG. The earliest SVR remodeling operation (reduction left
ventriculoplasty) involved excision of the necrotic portion of LV
and a portion of viable tissue from LV (Batista operation). However
it failed to change the natural history and course of ischemic heart
failure and has been largely abandoned. Excision of aneurysm with
direct suturing is rarely performed today. DOR operation of left
ventricular reconstruction involves endocardial patch plasty using
a circular suture and a Dacron patch to correct LV aneurysm.9
RESTORE (Reconstructive Endoventricular Surgery returning Tor-
sion Original Radius Elliptical shape) was performed by the restore
– group of cardiothoracic surgeons on 1198 patients.10 Ejection
fraction (EF) improved from 29.6  11.0% to 39.5 12.3% (P
< 0.001); LVEDV decreased from 80.4  51.4 ml/m2 to
56.6  34.3 ml/m2 (p< 0.001) and overall 5 year survival was
68.6  2.8%. RESTORE surgeons concluded that SVR improved LV
functions and was highly effective therapy in the treatment of
ischemic cardiomyopathy with excellent ﬁve year survival (68.6%).
However RESTORE is major cardiac surgery which requires
sternotomy, cardiopulmonary bypass and expert surgical team.
The concept of ventricular partitioning device (VPD) which can
be delivered percutaneously was conceived in 2005 and resulted in
the development and reﬁnement of “Parachute” device (Cardio-
kinetix Inc, Menlo Park, CA, USA). It is a novel trans-catheter device
for ventricular partition which tends to reverse LV remodeling in
patients with myocardial infarction and treat heart failure. The
device is under advanced stage of investigation in Europe, USA and
China. Recently it has been CE approved in Europe
The parachute device (Cardiokinetix Inc, Marlo Park, CA, USA) is
deployed at the apex of the LV cavity via percutaneous route under
mild conscious sedation and local anaesthesia (Figs. 1 and 2). The
ﬁrst published description of the parachute device and its
deployment was made by Sharkey et al. (2006)11 from the
University of California, CA, USA. The original parachute device was
available in two sizes but it is now available in eight sizes (65/65S,Fig. 1. Parachute partitioning device.
Please cite this article in press as: S. Gupta, Percutaneous left ventricular
doi.org/10.1016/j.ihj.2016.11.32475/75S, 85/85S, 95/95S). Brieﬂy the device consists of a conical, self
expanding nitinol frame covered with an ePTFE impermeable
membrane. The NITI frame is in the conﬁguration of an inverted
umbrella. The device has a radio-opaque atraumatic polymer foot
attached to the apex of the cone. The foot projects 2 mm to anchor
the device polymer to the apex of the LV. The conical frame is
supported by struts. The whole device is advanced over a wire via
14/16F sheath in the femoral artery to the left ventricle till the foot
abuts the apex under the guidance of transthoracic echocardiog-
raphy (TTE) and left ventriculography. The NITI frame is self
expandable but the device has a built in balloon which can be
inﬂated to assist in full expansion of the frame. After the device is
successfully implanted, the balloon is deﬂated and delivery
catheter is withdrawn leaving the device in left ventricle attached
to the apex. The whole procedure of implantation takes 1–2 h for
completion. Once the device has been successfully implanted, the
anchors engage the myocardium of left ventricle and stabilize the
device preventing its dislodgement and migration. The occlusive
membrane forms a barrier and separates LV into a lower akinetic
portion (including the apical aneurysm) and a larger upper
dynamically active LV. In view of the separation of LV into two
parts, device is also called ventricular partition device (VPD). Post
operatively, the patients are kept on prophylactic warfarin for 3
months or more along with optimal medical therapy (OMT).
VPD device divides LV into (a) an upper dynamic active
contractile chamber with reduced LV volume and diameter with
improved diastolic compliance and (b) a lower static akinetic
chamber with a compliant parachute device, which provides an
outward force at the anchors to facilitate diastolic ﬁlling of upper
chamber. The ﬂexible frame allows the device to follow the
contractions of the left ventricle. Parachute device makes LV into a
more elliptical/conical shape and allows torsional contraction with
reduced stress on the wall of upper chamber of LV.
Careful study by 2D-Echocardiography (2D-ECHO) and 3-
dimensional cardiac computed tomography (Cardiac CT) should
be done before undertaking ventricular partitioning device
implantation. 2D-ECHO determines ejection fraction (EF), LV wall
motion abnormality and presence/absence of apical thrombus.
Cardiac CT assesses the anatomy of LV architecture, geometry,
shape, trabeculations and endocardial calcium deposits. Presence
of apical thrombus, impaired trabeculae and severe calciﬁcation
impair the chances of successful implantation. Various inclusion
and exclusion criteria are depicted in Table 1.12,13
2. Objectives
The aims of the present study are to describe the “Parachute”
device brieﬂy, outline the procedure for implantation and present
the results of various published reports and trials with the aim to
determine its efﬁcacy, safety, indications & complications.
3. Methodology
The literature on percutaneous ventricular partition (Para-
chute) device was searched and the results critically analyzed.
Besides recent journals, we searched Med Pub, Mediscape, recent
AHA/ACC/ESC congress 2014/2015 for percutaneous ventricular
restoration and Parachute device. We also searched the ofﬁcial site
of Cardiokinetix Inc, Marlo Park, CA, USA for the latest information.
4. Clinical data
The ﬁrst in man successful implantation of parachute device in
a patient of chronic ischemic heart failure was performed in
Europe (Belgrade and Serbia)11,14,15 with follow up for 3–12
months. Sagic et al.16 implanted parachute device successfully in restoration in chronic heart failure, Indian Heart J (2016), http://dx.
Fig. 2. Parachute device, delivery catheter & delivery system.
Table 1
Ischemic heart failure: criteria for inclusion and exclusion of patients for VPD.
Inclusion Criteria Exclusion Criteria
1. EF 15–40% 1. Idiopathic dilated cardiomyopathy.
2. Presence of akinesia or apical aneurysm of the anteroapical region of LV 2. Clinically signiﬁcant reversible/treatable IHD by CABG/PCI
3. Presence of appropriate anatomy of LV for device implantation as under:
(a) LV end diastolic diameter 57–70 mm
(b) LV wall thickness >3.5 mm
(c) LV apical diameter 4.0–5.0 cm
(d) Normal trabeculations and papillary muscles
3. Optimum medical therapy as per existing guidelines has not
been given for a minimum of 12 weeks.
4. LV wall thickness <3.5 mm, excessive calciﬁcation and
intraventricular bands
5. Extremely dilated LV > 70 mm
(EF: ejection fraction, LV: left ventricle, IHD: ischemic heart disease; CABG: coronary artery bypass surgery; PCI – percutaneous coronary intervention).
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infarction with heart failure. The device had to be explanted in two
patients (out of 15) due to displacement and nondevice infection.
The remaining 13 implanted patients were followed for 12 months.
Mean diameter of device attachment zone of LV was 56.4  6.1 mm.
8 patients were implanted with 75 mm device and 7 with 85 mm
device. The procedural time was 60.6  29.0 min and an average of
340  99 ml of contrast was given per patient. Clinical progress,
hemodynamic data and quality of life (QOL) vide Minnesota Living
With Heart Failure (MLWHF) Questionnaire scale and observations
are summarized in Table 2. The authors concluded that VPD (PVR)
was a safe and feasible procedure. 6–12 months follow up showed
reduction in symptoms and improvement in 6 min walk distance
and LVEF with reduced LVESV and LVEDV at 6 months. Successful
implantation of parachute device was done in 5 patients in a
Portuguese centre with reduction in LV volumes which are
surrogates of heart failure.17 During follow up for 6 months, renalTable 2
Functional capacity and hemodynamic data during 6/12 months follow up in 13
device implanted patients.
Parameter Baseline 6 months 12 months At 12mth
p value v/s
baseline
NYHA Class 2.2  0.57 1.28  0.46 1.23  0.43 <0.001
LVEF% 28  7 32  7 33  9 <0.05
LVESV (ml) 189  45 142  29 151  48 <0.001
LVEDV (ml) 260  47 208  33 222_ + 58 <0.01
6 min walk
(metres)
382  123 409  129 425  140 <0.05
QOL points
(MLWHF)
21.7  18.9 16.7  12.3 20.8  16.9 –
(Sagic et al.).16
(NYHA – New York Heart Association, LVEF – left ventricle ejection fraction, LVESV –
left ventricle end systolic volume, LVEDV – left ventricle end diastolic volume, QOL –
quality of life).
Please cite this article in press as: S. Gupta, Percutaneous left ventricular
doi.org/10.1016/j.ihj.2016.11.324function and cardio-biomarkers remained normal indicating that
there was no damage to the myocardium during implantation.
Muzzaferri et al.18 enrolled 39 patients in a multinational
nonrandomized longitudinal investigation. The device implanta-
tion was successful in 31 out of 34 patients (success rate 91%).
Patients were followed for 12 months. There was improvement in
NYHA Class, Quality of Life (QOL) and LVEF with reduction in LVEDV
and LVESV (Table 3). Major adverse cardiovascular events (MACE)
occurred in 5 patients (16%) and included emergent cardiac
surgery, device migration/embolism and re-hospitalization for
heart failure.
Costa et al.19 has reported 3 years outcome in 39 patients with
ischemic heart failure, NYHA Class II–IV, EF 15–40% and dilated/
akinetic anterior wall apex without the need of revascularization.
VPD was successfully implanted in 31 out of 34 patients (success
rate 91%). The hemodynamic data for 3 years was available in 19
patients. The cumulative incidence of HF hospitalization and death
was 16.1%, 32.3% and 38.7% at 12, 24 and 36months respectively.
LVEDVI and LVESVI decreased over 3 years and LV dilatation
decreased signiﬁcantly indicating reduction in LV remodeling
(Table 4). Similar favourable results were found in pooled analysis
of ventricular partition device in Parachute III European Post
Market Trial.20,21Table 3
Clinical and echocardiography data in 31 implanted patients.
Baseline 12 months P value
NYHA Class 3 1.5 <0.001
QOL (MLWHF) 38.6  5.1 28.4  4.4 <0.002
LVEF% 26.9  1.4 29.4  1.4 NS
LVESV (ml/m2) 93.6  4.1 79.5  3.6 <0.001
LVEDV (ml/m2) 127.2  4.2 110.4  4.6 <0.001
(Muzzaferri et al.).18
(NYHA – New York Heart Association, LVEF – left ventricle ejection fraction, LVESV –
left ventricle end systolic volume, LVEDV – left ventricle end diastolic volume, QOL –
quality of life, MLWHF – Minnesota Living with heart failure).
 restoration in chronic heart failure, Indian Heart J (2016), http://dx.
Table 4
Clinical outcome of 31 implanted patients.
(A) Three-year Outcome
End of 12months End of 24 months End of 36 months
No of patients (n = 31) 28 27 23
Mortality 2 2 4
Cardiac transplant/VAD 1 2 2
Hospitalization for HF 4 9 10
Stroke 0 1 4
(B) Hemodynamic data in 19 patients (mean values)
Mean Data Baseline 12mth P value 24mth P value 36mths P value
LVEDVI (ml/m2) 125.7 108.9 0.0001 108.9 0.0057 114.4 0.0095
LVESVI (ml/m2) 89.6 76.7 0.006 76.7 0.0130 87.0 0.4792
LV Length
(cm)
10.1 8.8 <0.0001 8.9 <0.0001 8.6 <0.0001
LVEF (%) 28.9 30.0 0.5737 30.0 0.8544 27.0 0.0132
(Costa et al.).19
(VAD – ventricular assist device, HF - heart failure, LVEDVI – left ventricle end diastolic volume index (ml/m2), LVESVI – left ventricle end systolic volume index (ml/m2), LV –
left ventricle, LVEF – left ventricle ejection fraction).
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A meta-analysis of VPD therapy with implants in 91 patients
with ischemic dilated heart failure was presented at EURO PCR
2013.22,23 The success rate of implantation was 91%. 34 patients
belonged to Cohort A and US Feasibility, 47 to Cohort B and 9 to
Parachute III. The key inclusion criteria were NYHA II–IV, EF 15–
40%, LV wall motion abnormality and presence of adequate LV
anatomy for device implantation. The key exclusion criteria were
untreated reversible ischemia, severe AR or MR and recent history
of revascularization (PCI/CABG) or insertion of CRT/ICD. Mean age
of 91 patients was 60.7 years, male 88% with H/o smoking in 77%,
stroke 11%, hypertension 65%, diabetes 34%, dyslipidemia 85%, ICD
34%, CRT 9%, prior PCI 77% and CABG 15%. The average duration
since initial MI was 40 months before VPD implantation. Major
procedural complications (6.6%) were injury to aortic valve
requiring AVR, bleeding requiring blood transfusion, injury toTable 5
Meta-analysis of ventricular partition device in ischemic heart failure.
Author &
Reference
Trials Analysed Number
of
Patients
Successful
Implantation
(Number/%)
Follow-
up
Results 
PCR
201322
Thomas
et al.23
Parachute
Cohort A US
Feasibility Trials
Parachute III
Trial
100 91 (91%) 6
months
1.  NYH A improved 
By two class
By one cla ss
Mai ntai ned
2. QOL improved an 
dista nce  increas ed f
to 385 metre s (p <  0
3.  LVE SV red uced  by
(175 to 134)
4.  LVEDV  red uced b 
(241 to 194)
Abraham
et al.24
Parachute
Cohort A
US Feasibility
Trial
Parachute III
Trial
134 128 (96%) 12
month
1. NYHA improved
2. QOL improved. 6
3. LV Function imp
increased EF.
4. Combined risk o
(P < 0.001)
NYHA: New York Heart Association; LVESV: left ventricle end systolic volume; LVEDV:left
MACE: major adverse cardiovascular events; HF: heart failure; EF: ejection fraction.
Please cite this article in press as: S. Gupta, Percutaneous left ventricular
doi.org/10.1016/j.ihj.2016.11.324mitral valve and LV wall. Combined mortality and rehospitalization
for HF were 17.9% at 6months. Post implant NYHA improved by two
class of NYHA in 27% and maintained in 33%. Mean LVESV and
LVEDV also decreased by 23% and 20% respectively with mild
improvement of 6 min walk distance .
Abraham et al.24 published a meta-analysis on VPD in 134
patients with two year data. The patients belonged to Parachute
cohort A, Parachute US Feasibility and Parachute III. The device
implantation was successful in 128 patients (96%). The rates of
stroke, all cause death and combined HF hospitalization & death
were 2.4%, 2.3% and 8.8% respectively. There was improvement in
LV function (p < 0.05) assessed by reduced LV volume indices and
increased EF. NYHA class also improved from a mean base line
2.5  05 to 1.9  0.7 (p < 0.001). 6 min walk improved from 360
metres at baseline to 391 metres at one year. Combined risk of
mortality and HF hospitalization was reduced by almost 50% on
two year follow up.MACE
27% 
(P< 0.001)
35%
33%
d 6 minute walk 
rom 363 metres 
.05)
 23% 
y 20% 
(i) Major procedural
complications 6.3%
Injury to:
AV: 2 patients
MV: 1 patient
LV: 2 patients
(ii) Bleeding requiring blood
transfusion (2 patients)
(iii) Post procedural MACE
Stroke: 1 patient
Embolism: 1 patient
(iv) Combined mortality and
HF hospitalization 17.9% (17
patients)
 from 2.5  0.5 to 1.9  0.7 (p < 0.001)
 minute walk improved from 360 m to 391 m
roved (P < 0.05) with reduction in LVEDV and
f HF/mortality reduced by about 50% on follow up
Stroke 2.4%
All cause mortality 2.3%
Combined death and HF
Hospitalization 8.8%
 ventricule end diastolic volume; AV:aortic valve; MV:mitral valve; LV: left ventricle;
 restoration in chronic heart failure, Indian Heart J (2016), http://dx.
Table 6
On-going trials.
Name of Trial Type of Trial Number of patients enrolled and implanted Location of Trial End points
PRESENT TRIALS
Parachute Trial
Cohort A & B
Dual arm, open label multicentre Cohort A 19/14
Cohort B 59/54
Europe (14 centres) 6 month MACE, ECHO and CT
Parachute US
Feasibility Trial
Single arm, open label multicentre Patients 20
Implant 17
US (8 centres) As above
Parachute III
Trial (Parachute
vs OMT)
Enrolling 100 Europe (20 centres) 1. Mortality
2. Hospitalization for HF
FUTURISTIC TRIALS
Parachute IV Enrolling up to 560 Enrolling US (80 centres) As above
Parachute CHINA Trial Single arm, open label multicenter Enrolling China (7 centres) 1. LVESV1
2. NYHA Class
3. QOL
Parachute V
(Parachute vs
OMT)
Dual arm, open label multicentre Enrolling Germany (20 centres) 1. Stroke index
2. QOL
Adapted from the source – www.cardiokinetics.com (downloaded 21.1.16).
MACE: major adverse cardiovascular events, ECHO – echocardiography, CT – computerized tomography, OMT – optimal medical therapy, QOL – quality of life.
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Ladich et al.25 have examined the pathological features of 7
parachute devices which had been explanted at autopsy or before
cardiac transplant. The average duration of implant was 408 days
(15–1533 days). All had organized thrombus with development of
ﬁbrosis and neo – endocardial thickening at the edges of device.
Two implanted device (Duration > 300 days) had developed
fractures of the struts and foot; one had tearing of the expanded
ePTFE membrane. This study is a possible indicator of the life span
of the device.26
7. Comparison of surgical ventricular restoration (SVR) and
percutaneous ventricular restoration
SVR has been studied in RESTORE10 and STICH.27 In STICH
(Surgical Treatment of Ischemic Heart Failure) trial, beneﬁcial
effect of additional coronary artery bypass surgery (CABG) to
optimal medical therapy (OMT) was compared with medical
treatment alone in 1212 patients of ischemic cardiomyopathy.
Addition of CABG reduced sudden cardiac death and fatal pump
failure after two year of CABG. Percutaneous device is much less
invasive compared to RESTORE or STICH and is performed under
conscious sedation while SVR is an open heart surgery and requires
sternotomy, cardiopulmonary bypass. Parachute device provides a
more ﬂexible barrier while suture related scar in LV may produce a
more ﬂat scar in SVR. VPD provides a more elliptical/conical shape
of LV, while in SVR, it is operator dependent. Reduction in LVESV
and LVEDV are higher with VPD (23%) versus STICH (13%). Both
methods tend to improve NYHA Class and QOL. Post operative
complications and MACE appear comparable although surgery has
a little higher rate of complications and longer hospital stay. The
life span of VPD device is not known. It is not clear how long the
reductions in LVESV and LVEDV observed after device implantation
will continue to persist. However VDP is a novel innovation and its
safety, efﬁcacy and durability are expected to improve in future
with newer generation of device and further reﬁnement.
8. Futurisitic on-going trials
Parachute IV is a pivotal on-going FDA trial (Table 6). The trial is
expected to enrol 560 post LAD territory MI/HF patients in US who
have NYHA III–IV status with EF 15–35%, LV wall movement motion
abnormalities (Akinesia or aneurysm) and suitable LV anatomy
assessed by 2D-ECHO and cardiac CT. The end point of the studyPlease cite this article in press as: S. Gupta, Percutaneous left ventricular
doi.org/10.1016/j.ihj.2016.11.324will be all cause mortality, hospitalization for HF, QOL and
hemodynamic parameters. The study is likely to afford answers to
many queries. University of LOWA’s Heart Failure Programme
(USA) is currently following Parachute device implantation under
Parachute IV clinical trial. If found safe and cost effective, the
pivotal trial may pave way to its approval by FDA.
The parachute China trial and parachute V trial in Germany will
further add data to its safety, efﬁcacy and durability of the device.
9. Conclusions
VPD is under development through various clinical trials since
2006. Eight different sizes of device CE marking are now available.
Development of guide catheter and delivery system has reduced
aortic and mitral valve trauma. FDA approval is still awaited.
Clinical trials and two available meta-analytic trials have shown
reduction in LVEDV and LVESV which are surrogates of heart
failure. There is improvement in NYHA class and QOL. Success rate
of implantation has been over 90%. Continued clinical experience
and Parachute IV & V trials may establish the future of this new
device in the management of post infarction heart failure.
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